Shop
Venetoclax / Venclexta (Everest)
Original price was: £300.00.£256.00Current price is: £256.00.Venetoclax (also known as Venetoclax; Brand name: Venclexta) is the first selective targeted therapy designed to inhibit the B-cell lymphoma-2 (BCL-2) protein, helping promote apoptosis in cancer cells and suppress tumor survival.
MedFind provides overseas sourcing services for Venetoclax through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Larotrectinib / Vitrakvi (Everest)
Price range: £269.00 through £554.00Larotrectinib (Brand name: Vitrakvi) manufactured by Everest Pharma is a targeted therapy used for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring NTRK gene fusions, regardless of where the cancer originated in the body.
Larotrectinib became the first FDA-approved tumor-agnostic targeted therapy based solely on the presence of a specific genetic mutation rather than cancer type or tumor location.
Clinical studies demonstrated efficacy across 17 different adult and pediatric tumor types, highlighting its broad-spectrum anticancer activity in patients with NTRK fusion-positive cancers.
Lorlatinib / Lorbrena (Everest)
Original price was: £409.00.£347.00Current price is: £347.00.Lorlatinib (also known as Lorlatinib; Brand name: Lorbrena) is a third-generation ALK and ROS1 tyrosine kinase inhibitor (TKI) with broad coverage against ALK resistance mutations and strong central nervous system (CNS) penetration.
Lorlatinib demonstrates potent activity against resistance mutations that develop after treatment with crizotinib and second-generation ALK inhibitors, making it an important targeted therapy option for advanced ALK-positive non-small cell lung cancer (NSCLC).
MedFind provides overseas sourcing services for Lorlatinib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.
Sotorasib / Lumakras (Everest)
Original price was: £450.00.£391.00Current price is: £391.00.Sotorasib, also known as Sotororese (generic name: Sotorasib, brand name: Lumakras, code name: AMG510), is a covalent inhibitor of the KRAS G12C mutant. It binds to the KRAS G12C mutant protein, locking KRAS in its inactive state and thereby irreversibly inhibiting its activity.
Clinical trial results showed that patients treated with Sotorasib achieved an overall response rate (ORR) of 36% (95% CI: 28–45), a disease control rate (DCR) of 81% (95% CI: 73–87), and a median duration of response of 10 months. After more than 40 years of research on KRAS-mutant oncogenic proteins, Sotorasib became the world’s first approved KRAS G12C inhibitor.
Gilteritinib / Xospata (Everest)
Original price was: £412.00.£396.00Current price is: £396.00.Gilteritinib (Brand name: Xospata) is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor approved for the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations.
It is also being actively studied in multiple clinical trials for additional AML subtypes and combination treatment strategies, including first-line therapy, maintenance therapy, and use in combination with chemotherapy or other targeted therapies.
MedFind provides overseas sourcing services for Gilteritinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Capmatinib (Everest)
Original price was: £512.00.£429.00Current price is: £429.00.Capmatinib (Capmatinib) is a selective MET inhibitor used for the targeted treatment of patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. By inhibiting abnormal activation of the MET signaling pathway, Capmatinib helps effectively suppress tumor cell growth and spread.
Capmaxen by Everest Pharma is a high-quality generic version of Capmatinib, offering patients a more affordable treatment option. MedFind provides overseas sourcing services for Capmatinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Adagrasib (Everest)
Original price was: £512.00.£461.00Current price is: £461.00.Adagrasib (Brand name: Krazati) is an FDA-approved KRAS G12C targeted therapy indicated for the treatment of advanced non-small cell lung cancer (NSCLC).
It is the second KRAS G12C inhibitor approved following sotorasib and has demonstrated activity in certain patients who developed resistance to previous KRAS-targeted therapies.
MedFind provides overseas sourcing services for Adagrasib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process, along with authenticity assurance and fast shipment availability.
Olaparib (brand name: Lynparza, Lipuzhuo; Beacon).
Price range: £468.00 through £591.00Olaparib produced by Beacon (generic name: Olaparib; brand names: Lynparza, Lipuzhuo) is a PARP inhibitor originally developed by AstraZeneca. It has been approved by the FDA for the treatment of various cancers, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.
It works by inhibiting DNA repair enzymes, preventing cancer cells from repairing their DNA, which leads to cell death and helps delay or stop tumor progression.
Beacon Pharmaceuticals was founded in 2001 and is one of the largest and most technologically advanced manufacturers of oncology and antiviral drugs in Bangladesh. Its products comply with international GMP certifications, including those from the US FDA, UK MHRA, and Australia’s TGA.
Erdafitinib (Everest)
Original price was: £600.00.£499.00Current price is: £499.00.Erdafitinib (Brand name: Balversa) is an oral pan-FGFR tyrosine kinase inhibitor used for the treatment of patients with locally advanced or metastatic urothelial carcinoma carrying FGFR2 or FGFR3 genetic alterations, especially in cases where platinum-based chemotherapy has failed.
MedFind provides overseas sourcing services for Erdafitinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Tucatinib (also translated as Tukatinib; brand name: Tukysa, Everest)
Original price was: £790.00.£570.00Current price is: £570.00.Tucatinib (also translated as Tukatinib; brand name: Tukysa) is able to inhibit the growth of tumor cells that overexpress HER2.
In 2020, the U.S. FDA approved tucatinib in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have previously received one or more anti-HER2-based treatment regimens.